>NC_015578:3011133:3011133	putative von Willebrand factor, type A
VIPSSPNPVELEPGQVKTITITVSAESGNTKQYIIRATRLTATQTDATLRTLTYNGVTVPGFSPTGDTEYTFTVPYATESVTLAATLVNTAGEVILPTPNPVELVPGEEKTITVTGKAASGDTKDYTIKVTRLHASANLSSITINGVQVPGFSPTGSSYTITVPYAGNETITVAATGNAEGSTLDYSIDPDSPVALVAGVEKTITVKGKSVSGAIKEYTLIVTRALPSDNAKLSSLSISPWALSPPFAPDTLEYTASVANGITSLTVSASKQDPLAAAPTLPTNPVSLNVGANTIQVTVHAEDPAIAQTYKIVVTRRPEDLNNAKLATLSVNGVPVPGFDPDIGGPYAVNAAYRIDTITLAAQTEEEKTGVTLSGDTLDTAHPFASEVSEGGTKTFTVNSAKGTGTKTYTIVVTRLPASTINTLSSITVSAGTLTPKFTSTGNFYSVEIPYLTPNVTVNAVKTNAEATVVLSVSNGLAITNGVVTLNASTPYPFTVTATVTPESLGAPERYYIEFRQQGQLSVTITQPDEVIDLATDIGNNLSIAGGGYITVTADISGISNFEWYVDGTSIGQGFDNFNGTYSVNITAASVGVGTHTVLLQFYKDEIYYGSEVSFKVGK
>NC_015578:3011133:3013004	putative lipoprotein
MKKHFGTISGNTIALAGLFLAAILGFGACANPLSSSPGGAKPSGVSGVEIKIANGTERTLSPDNKSFTSYDVYFSDRSNPDFKETYTGTTVTKNLSPGTWDIYVLAYVGKVQSAFGSTSSVPVFNGQSTGVTIQLSPISPFTSPGDRGSFTYSVQFDKQGVQDYPIPGATLSLSPLSGINSASKNLLNEPSGTIPLAPGFYRLLIQVANNYGMASRSEVVHIYAGKDTAALPISFSPEDFGPFVTINGTVELGGRDDIVGGNIELYADLTFPFISSARASIDPKTGNWTARIKPYVSSTLLYPRLSLQFTDGSSISTEDPSGFDAYNFGADIIDAGSITVPDIHKYTLRGAIDLSEIADADITLPSTVLVYIQRSGVILNYAYLPSARNGNWELAIASKEDLSSTEVSIVLLLSSGIVSTTEYRTAKITGPVTTGLNFKPKVITEDGTPKLTIGSSGQSTFIFKPAGSGSYSLGVIPVIDGDAATLTGIAPSPATNLGRYILSAGTLYSITVSGTANSNYTIALDGQQLRSNADLSDLEVVGDVDGLLTLNPGFSAGITDYEVSYTLTSYHIFVNATADDSNALRLYITNNGSSYSYSSGESISLSPGTNIIKVEVITEAGRLKPYTITVTRQLMSPTPTADITSVANAPDLGYVSFFLTNNPVYTKTTWKVYDAPTGNTEKPGVTAVNLDSTLFLIDEASVTDSVTYYVSATEEGGLESVGRLALTVSNPGEISSLSFNGDIEISYEGSSSPIIISQSGSGYLSTIDLSVSGDYESFSWRVDNVSNIAVTNSITLDATAYETRNHFVTFKGVKDGIPYAKELPFTVVE
>NC_015578:3011133:3015505	putative von Willebrand factor, type A
MKLFGNKQRALSPITCAAGIVLLAGLLALTGCANPLNSPADNTVGQGLGLVTITIGETGARNLYPNPTGFTNYELSFAPISGPAFYGAIPASVAKSDSSFPPISLIPGTWTITAKAYNGSTQVAETAVEVTVVAGELVTKNIILKPITGAGAGTFDYEVTNADDVDFDDGSELTLSDLSGNPIYTYNLSSVQSGTDSVPAGIYDLSIVIKKDGGITGTTEVVFIYPGLTTVAHFIFGNGEIYSGTTSNPAFVATSLSKTEVVQPSITFELKNDTELTGATWKVYDAEDDGDDITDTVVPTIESSNKLTLTAVSNNITAGDYWVTAQAPGKFESATRVKLTVEPNPLQNETFTVVDGIGDPGLNNIYLEGGFVKIGDDDGGFIDHNPDTDPAYKPLAVFLGLTGVEPDDQIVFDEYGKILKLTKVDITYDITFAVDDKYLPAIADVLTLTGNASKSFEVTGDALTGKTVILDSTSSPTYNFYGVSVLPYDTNDVTISAEDDDTDGKVVTLLDGGSADATVSVLDEAVDKLVLGTNAPSAISNEKSGLVIDVGTNAGITITATQPTTVVTDKLATGTVTVDGYSTAAITIDGVSITPVGYTDAIVTKTDYYTLELDAGDTTATVAIEYDSAITELTLVDTNLEAISNANTATVINVGSISGVEITAAVDTTVVTTELSDSNTVVLIGDKTFTLLVLDDGGYEDDPTPGTVTGSTNGYVYTYLNDNGNENTEFAPIDDDSFSLTSDSGTVTVTVSDITP
>NC_015578:3011133:3018215	hypothetical protein
MNNKESDTFTEIPADKKRVQLKAEDDLLDISQDPIFKAVLTQDTPASRNALRFLVSAAIGQPVTIISVSTNEPPVRGIRDRQLRYDISVKFNDGSLGDIEMTVYPDVYEHFRQEYYLARLFTTQDIKGTELGYSNLKPTWQISLLGENIHADNALVHQFRYYDKENNLPFRGLTSIIDWKVGWNPASTINFLSNEEPGSLLQGSSCGTAKGGTVPGKAGLRDGAYRALGSIFPV
>NC_015578:3011133:3018879	meiotic expression up-regulated protein 1/2
MAPIERWAVFFRYSQESERRGLINEILDQEEGIQMATEELLLISEDENRRFQLEHELKNFLDIKCGMVDARWEGYKQAKEEDAGIIQEKDAAIQERDTALQEKDREIAELRAKLGRP
>NC_015578:3011133:3019425	helicase domain/SNF2 family domain-containing protein
MKTIDNLEIKLIDKLLGEIKQETKISIVASCFSIYAFEVLKKQFDTIAELRFIFSSPAFTASPPDSDTQQLMREKDLAGTEFEFGLRNKLTQAAIAKECSEWIKNKVKFYSNTTRENMPGFMVFENGESSSSYTPIQNFTTVDLGYQKGNDAYTLITHAEAPQSIRFLQQFDKLWKDSKKTKDVTDQVLAALKTLYCQNSPQFVYYITLYNIFKDYLEELSTTELPNEKTGFKNSAIWSKLYDFQREAAISIIQKLERYNGCILADSVGLGKTFTALGVIKYYESLNKSVLVLCPKKLHNNWKTFNTNNVNNPVFRDHLRYDILFHTDLLRERGESATGIDLSSYNWANNDLIVIDESHNFRNGGTLNLKDPKENRYDRLLNKVIKGGVKTKVLMLSATPVNNKFQDLNNQLKLAFEGQTEDINTKLEFTHNQGIDYIFKQAQSVFDNWSKRPPEEKTTESLLRALDFNFFNLLDSVTIARSRKHIENYYNSKAIGLFPTRNRPIAHHPALTNEKNMISYYEIYDFLEKLTLSVYMPSNFLSLDKITKYQEGAEYKNRLTLVGRELGILQLMNINLLKRLESSVQSFFISLTHLKELINNMLKKIDAFEKTKSGADVFLEDLPFQTNELDEDDENSDYFTVGKKIKFSLEDIDLKKWKNALGEDLIILQALLNKISVITPKQDNKLQTLLQVIDDKFTNPINNDNKKILIFSAFADTAEYLFHHIGNYIEEKYHLHAAMVSGSKTLTTIPKINADFNSVLSYFSPRAKTKDIEDPKLREEALQKFLKYPIDVLIGTDCISEGQNLQDCDYCINYDIHWNPVRIIQRFGRIDRIGSNNNCIQLVSFWPDLDLDEYINLKERVESKMKAVIIASTGTLEDNPIEEEKGDLEYRKAQLERLQKEVIDIEDMQTGISIMDLGLNEFRLEIQEYFSHHRDIEKFPNGLFAVLEPDEELKQGAIFILKYKGKNIDKQNRLHPYFIIYISENGEIIHDYLSSPKTLNLLKKICQSSFSSQSTPCTDFSPISNDIFDMSQYYLLLEKAISSVIDTKAAKSDVKSLFNKGKTTFLDTKNINIKDFEIISYFIIKGRSYD
>NC_015578:3011133:3022690	Sel1 domain-containing protein
MINYFNLNKECIVNEESPKDEIITNIKDNNYKFDKLKIDRFNALVKTIKTLAVLNSENTNIEALSTSEFDYSEIIILEIELNYYSEVNDFFLFANLLGRHMPKLLVLLIKYENRYKIIVNKVRENKKNNLLTVVDDILITYWIYPDSPSEISKDIISKLNINKYQAANLFELYKSLNNNLRQFKCRHMTLYSNDFSYVLSNIFKLNTEDCEYLIECIKTKCLHEVSRPPLSKKYRDIYSSQNNRNTIARIFYDYEDVWYILNYHPELKNIMRRMEINNMRDLLDFSYERRRENQQQKTPWWSYSNDSVNNIEEKEIREVSKNTINHIINLDKSLIEEAIAFETGIGIGQNTNKAIEKYLDAFELGIRIIDHIINTDTMVKLAQNISVKYKNKKIESFELLIKASENGNAKAMLYLGRYYLESETKDYAKAIEYFMKAIALGDDNAIIELAKLCKENIDIIEYINDIKILMKTAGKFEDGIKLNKDYEIAFKLFEKAANLDDGEAQYSVGRFYEKGMFVSKDIQEALNWYTKASEKQIPYALEKIAYFLQHGVAGEKDIQKANHYYKKAAQGFQKMADRNDSKAQYLLGQLYKYGIGVKKDIPLFLEWNEKSTATGYKKAQYEYGYSYELKGNIPMAFGWYKKSAEQNYSKAQYKLGLYYEDQDEMDEAFKWYLKAAENGHIESMESLAFCYEKGEGIDKDLEKAKEWYSKAKNMKKY
>NC_015578:3011133:3024882	[citrate (pro-3S)-lyase] ligase
MTDLQKIRNPGTDPVLEKLLASFDLTLPEDTDDNLGLYENGALLGCGFLKGNMIQCLAIDKSRQREGLSAVLVTALIKLAAARGIHYLRVITKPSMAPLLSGLGLQKVADASPYAVFLEFGRPGSAERMAHFRALAAEVPFTAGKQECTVAGKQGAELPAAGEQGCAEFPSAGKQGASCLVMNCNPFTLGHRWLIEQASRENPWVWVLAVEEDRSLFPFKDRLHLMEAGTGDLKNVRVIPGGEYVISSLTFPAYFTRNADLASAQGALDAAVFAALIAPALGVRRRYVGTEPLSLSTELYNQALRERLPQAGIELVELDRISRGGRVVSASAVREGIVKGDWDLVRDMVPDTTWEYLRYNPE
>NC_015578:3011133:3025967	citrate lyase subunit alpha
MSKLVASLEEAIRAAGLKDGMRISFHHHLRNGDFVLNMTLALIAKMGIRDLTVNASSLFDSQEPLLAHIKNGVVTELETNYMSPVIGKAVSEGILAKPVIFRTHGGRPGAIETGVTPIDVAFIAAPTADNQGNCTGRVGKSACGSLGYAFADAMHAKKVVAITDNLVEYPLGDYSISETYVDYVVKVDAIGDPEGIVSGTTRMTRDPLALRIADLSARVIRASGLLKDGFSFQTGAGGASLAVGQSVQDIMTREGIKGSFALGGTTGYLVDMLEAGCFQTIMDVQCFDLKAVESLRNNPRHVEISASHYASPGAKSSASQNLDVVVLGATEIDVNFNVNVHTDSNGYIIGGSGGHSDVAAGAKLAMVIAPLSRARLSIVVDKVLTTTTPGKTIDVLVTQYGAAVNPLRDDLRKELARVGIPLKEMGELRKIAEDLNGVPEKCERGSRVVGKVLYRDGSLIDEIYQVKEA
>NC_015578:3011133:3027369	citrate lyase subunit beta (Citrase subunit beta) (Citrate(pro-3S)-lyase subunit beta) (Citryl-CoA lyase subunit)
VRRSVLFLPGNNPNLLINGSVLGADGIIFDLEDAVSPDDKDAARILVSHALGALKFDKCEIIIRINALDTKYWEKDLEAVVPLGPDMILPAKVGCAEDIFTLTKKIEEVEAKAGITKIVKLLPLIETALGLENSFAIASANKRVSALLLGAEDLTADLRAPRTREGAEIAYARGRIVCAARAAGVDVFDTPFTDVNDMEGLRQDALLARSLGFTGKAVISPRHVDLVNEAFSPTDREITYAHRVFDAIASAKEQGKGAISLDGKMIDAPIVERARIILETARELGKGNDHE
>NC_015578:3011133:3028245	citrate lyase acyl carrier protein
MQVIKNAVSGTLESSDIYIEVLPGKGVEIDLSSPVIRQFGESIKKTMLGVVRGLGIEDVHIRAHDQGAMDCVIQARLETALLRAGEEN
>NC_015578:3011133:3028610	hypothetical protein
VVLKDVAVAAIAAWLKVSSIILLKLAFRHINRLASKLENRRRRGWERPWGRLWNSLPEETYRAP
>NC_015578:3011133:3029211	aminobenzoyl-glutamate utilization protein B
MGDKKRLVELIDGKKEIFAKLNDRIWEFAEIRFSLKQSADALCEVFEKEGFAIERGVAGMAHAFIATYGKGNPVIGILGEYDALAGMDQVAGIAEKKSLKPGTPGHGCGHAALGAGAAAAAVGIKDYMKEKGLAGTIKYYGCPAEESGSGKAYLARAGAFNGLDSVLTWHPMMENALMGVSTLANYQIFFSFKGRSAHAAMSPDQGRSALDAAELMNVGVNYLREHVIQEARIHYAYTDVGGGAPNVVQASAELLYFIRAPRQSQVQEIYERVVDIAKGAALMTGTTMNIRWDSACANVLVNEVLSKALYSNMQWLGPNNYTKEEIAFAKTLVDSLDESSKKGIPAKAARTFFDRSPEDLAKIAAKPLIDDIAPYAFTDKAIPASSDVGDASWHAPTAQFTTACYPHGTVSHSWQVVSTGQSSMVHKGLDQAGKIIALTALDLLENPKMIEDAKAEFKRRLGGEEYHCPIPAEVMPEA
>NC_015578:3011133:3030649	hypothetical protein
MSDKKTLGIDAESKAHIDSMHRLGRFGAVIAIAIMIGMPVIAGIYFNAMPGLVKILTASVGLLALFVPGAISEVIAYTPIFGSSIYLAQITGNIMNLKLPVANTALQLLDVESGTEEADIVTSIAVSVSSFVTIIVIFLGVLLILPLRPVLTLPVVKLASGYIVPALFGSLAIGSIGSNIGGGIRTKGRLKGMILPVIVVAAVNIIVVYVIKQPMLLAFYQGFLMLALLPIAYFGTKLLYNKGQIQVLLPGEGK
>NC_015578:3011133:3031424	hypothetical protein
MSFYDVAGHWLIYLMVGIGILFVACLAVVSMRKSWKRAIAKGYPREKLMTVVKSAVSATIIPSLAIVIGFFALVPILGVPWPWWRLSVVGSVTYETMAADSAVKAAGLDMTKLSLATAEDFVLVMFVMSIGIIGGLFFSPFASKSIQAGTMKLKVGDKRWGALGSSVFFLVILVVFVVPMFLDYSKTGIVKLLTLVSSGLITVILNVVADKCKAGWLRGFTLAISLLLAMASSVLWFGLLK
>NC_015578:3011133:3032197	gamma-glutamyl-gamma-aminobutyrate hydrolase
MKPRIGIVSRYSTKSDLGVFAHQGLKNDTWQILSNAYIEAITDAGGLPIIIPIYQDPHLALEFIPFLDGILFPGGTDIDPAYYHEAPDPEGEIWALSPEMDALEMELGEKVLKDTNIPILGVCRGLQLFNILKGGSLYQDLKYSCATIAHGVDPAAELSSRAHEVILEKGSMLYGITGEETLKVNSYHHQTVKEIGRGLQVAARSTDGLVEALEGSDEGRFELFFQWHPEMLALKRCGADRPSRKIFSNFIEECGKSA